AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38605404 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural and functional lung phenotyping
Number of subjects: 530
Study 38605404 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning techniques
Number of subjects: 530
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening for plasma BKPyV-DNAemia loads monthly until month 9, then every 3 months until 2 years post-transplant (3 years for children)
Number of subjects: 0
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cytology screening at similar time points to exclude BKPyV-nephropathy
Number of subjects: 0
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of immunosuppression for patients with BKPyV-DNAemia loads >1000 copies/mL or exceeding 10,000 copies/mL, or with biopsy-proven BKPyV-nephropathy
Number of subjects: 0
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of allograft biopsy for children with persisting BKPyV-DNAemia even without graft dysfunction
Number of subjects: 0
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry for diagnosing biopsy-proven BKPyV-nephropathy
Number of subjects: 0
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney retransplantation subsequent to BKPyV-nephropathy if BKPyV-DNAemia is undetectable
Number of subjects: 0
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine graft nephrectomy
Number of subjects: 0
Study 38605438 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments (antivirals, vaccines, neutralizing antibodies, and adoptive T cells)
Number of subjects: 0
Study 38605658 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of psilocybin (25 mg)
Number of subjects: 59
Study 38605658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 38605958 — intervention group
Group type: EXPERIMENTAL
Intervention: BVAC-C injection at 0, 4, 8 weeks (Arm 1)
Number of subjects: 30
Study 38605958 — intervention group
Group type: EXPERIMENTAL
Intervention: BVAC-C injection at 0, 4, 8, 12 weeks (Arm 2)
Number of subjects: 30
Study 38605958 — intervention group
Group type: EXPERIMENTAL
Intervention: BVAC-C injection at 0, 4, 8, 12 weeks with topotecan at 2, 6, 10, 14 weeks (Arm 3)
Number of subjects: 30
Study 38606105 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAJB1-PRKACA fusion-based neoepitope vaccine Fusion-VAC-XS15 combined with anti-PD-L1 antibody atezolizumab
Number of subjects: 0
Study 38606105 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-L1 antibody atezolizumab
Number of subjects: 0
Study 38606174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation
Number of subjects: 414
Study 38606174 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 414
Study 38606196 — intervention group
Group type: EXPERIMENTAL
Intervention: van Cittert iterative deconvolution (VC)
Number of subjects: 0
Study 38606196 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-compartment PVC method
Number of subjects: 0
Study 38606196 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-compartment PVC method
Number of subjects: 0
Study 38606196 — intervention group
Group type: EXPERIMENTAL
Intervention: region-based voxelwise PVC method
Number of subjects: 0
Study 38606196 — intervention group
Group type: COMPARATOR
Intervention: non-PVC images
Number of subjects: 0
Study 38606196 — intervention group
Group type: EXPERIMENTAL
Intervention: LMEM-derived %ΔSUVR values
Number of subjects: 0
Study 38606277 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-rich artificial cerebrospinal fluid (MACSF)
Number of subjects: 71
Study 38606277 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 71
Study 38606277 — intervention group
Group type: EXPERIMENTAL
Intervention: MACSF
Number of subjects: 71
Study 38606277 — intervention group
Group type: COMPARATOR
Intervention: NS
Number of subjects: 71
Study 38606384 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg TU twice daily with meals, titrated to between 100 and 800 mg TU daily
Number of subjects: 155
Study 38606384 — intervention group
Group type: EXPERIMENTAL
Intervention: KYZATREX™
Number of subjects: 155
Study 38606412 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Through Play plus Culturally adapted Cognitive Behaviour Therapy (LTP+CaCBT)
Number of subjects: 130
Study 38606412 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 130
Study 38606412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LTP+CaCBT and PE)
Number of subjects: 130
Study 38606524 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP monitoring (n=79)
Number of subjects: 157
Study 38606524 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=78)
Number of subjects: 157
Study 38606621 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) titration during DISE
Number of subjects: 25
Study 38606776 — intervention group
Group type: EXPERIMENTAL
Intervention: SingHypertension intervention (clinician training, subsidized medications, nurse-delivered motivational conversations, telephone follow-ups)
Number of subjects: 0
Study 38606776 — intervention group
Group type: EXPERIMENTAL
Intervention: SingHypertension intervention
Number of subjects: 0
Study 38606776 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38606777 — intervention group
Group type: EXPERIMENTAL
Intervention: Apilimod dimesylate 125 mg twice daily for 12 weeks
Number of subjects: 15
Study 38606777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 38606958 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF (240 µg with or without aluminum hydroxide)
Number of subjects: 263
Study 38606958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 38607238 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency or longer duration of daytime nap
Number of subjects: 3069
Study 38607238 — intervention group
Group type: COMPARATOR
Intervention: Naps
Number of subjects: 3069
Study 38607276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation
Number of subjects: 0
Study 38607276 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38607410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 326
Study 38607494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention
Number of subjects: 578
Study 38607494 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 578
Study 38607515 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (digital tools, lessons, adaptive goals, tailored feedback, text messages, Facebook prompts)
Number of subjects: 280
Study 38607515 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 280
Study 38607538 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab-chemotherapy
Number of subjects: 141
Study 38607538 — intervention group
Group type: COMPARATOR
Intervention: placebo-chemotherapy
Number of subjects: 141
Study 38607628 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (6 sessions over 3 months)
Number of subjects: 138
Study 38607628 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard institutional resources)
Number of subjects: 138
Study 38608150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy (HAIP-SYS)
Number of subjects: 31
Study 38608217 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucellosis patients with osteoarthritis
Number of subjects: 429
Study 38608217 — intervention group
Group type: COMPARATOR
Intervention: Patients without osteoarthritis
Number of subjects: 429
Study 38608236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Flower Cannabis Use
Number of subjects: 0
Study 38608236 — intervention group
Group type: EXPERIMENTAL
Intervention: Edible Cannabis Use
Number of subjects: 0
Study 38608236 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38608658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (escalated from 3×1 to 3×3 capsules of 267 mg/day within 3 weeks for 12 months)
Number of subjects: 51
Study 38608658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 51
Study 38608691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (240 mg every 2 weeks)
Number of subjects: 176
Study 38608691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO3 plus IPI1: 3 mg/kg every 2 weeks plus 1 mg/kg every 6 weeks)
Number of subjects: 176
Study 38608691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO1 plus IPI3: 1 mg/kg every 3 weeks plus 3 mg/kg every 3 weeks for four cycles then nivolumab 240 mg every 2 weeks)
Number of subjects: 176
Study 38608691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (pooled NIVO1 plus IPI3)
Number of subjects: 176
Study 38608691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 176
Study 38608691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO3 plus IPI1)
Number of subjects: 176
Study 38608691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO1 plus IPI3)
Number of subjects: 176
Study 38608693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg/day
Number of subjects: 17
Study 38608694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg daily
Number of subjects: 18
Study 38608752 — intervention group
Group type: EXPERIMENTAL
Intervention: WOOP+MOVE! or TeleMOVE!
Number of subjects: 0
Study 38608752 — intervention group
Group type: COMPARATOR
Intervention: MOVE!/TeleMOVE! alone (control)
Number of subjects: 0
Study 38608752 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MOVE! or TeleMOVE!)
Number of subjects: 0
Study 38608871 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversity of foods purchased
Number of subjects: 586
Study 38608871 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 586
Study 38608871 — intervention group
Group type: EXPERIMENTAL
Intervention: Production diversity (among nonbreastfed children)
Number of subjects: 586
Study 38608871 — intervention group
Group type: EXPERIMENTAL
Intervention: Household food purchase and food production diversities
Number of subjects: 586
Study 38609174 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBOVAC aspiration catheter
Number of subjects: 100
Study 38609315 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention on influenza vaccination
Number of subjects: 3036
Study 38609315 — intervention group
Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 3036
Study 38609316 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab administered starting on day 4 post-ASCT and then every 28 days until 1 year post-ASCT, combined with autologous lymphocyte infusion and lenalidomide maintenance (cycles 4-12).
Number of subjects: 15
Study 38609316 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab and autologous lymphocyte infusion post-ASCT.
Number of subjects: 15
Study 38609316 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlative analysis of immune microenvironment post-ASCT.
Number of subjects: 15
Study 38609322 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 0
Study 38609322 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 0
Study 38609322 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0
Study 38609322 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors (TNFi)
Number of subjects: 0
Study 38609522 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA) entitled RealRisks
Number of subjects: 50
Study 38609684 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam-based total intravenous anesthesia
Number of subjects: 96
Study 38609684 — intervention group
Group type: COMPARATOR
Intervention: Desflurane-based inhalational anesthesia
Number of subjects: 96
Study 38609684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 96
Study 38609723 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based Clinical Decision Support System (CDSS)
Number of subjects: 37
Study 38609723 — intervention group
Group type: COMPARATOR
Intervention: Control (Clinician recommendations)
Number of subjects: 37
Study 38609737 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict 6-month wheat-free diet (WFD)
Number of subjects: 201
Study 38609987 — intervention group
Group type: EXPERIMENTAL
Intervention: Maytenus senegalensis (800 mg every 8 hours for 4 days)
Number of subjects: 12
Study 38610004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase (idursulfase-IT)
Number of subjects: 56
Study 38610005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-EEG assessment of spike frequency in patients with AD
Number of subjects: 24
Study 38610005 — intervention group
Group type: COMPARATOR
Intervention: Arterial spin-labelling MRI (ASL-MRI) measurement of rCBF in the hippocampus
Number of subjects: 24
Study 38610031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 40 mg twice daily every 3 weeks for up to 1 year or until disease progression
Number of subjects: 0
Study 38610031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib
Number of subjects: 0
Study 38610034 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with ProPrems® (Bifidobacterium infantis, Bifidobacterium lactis, and Streptococcus thermophilus) diluted in 3 mL breastmilk per day until gestational week 34
Number of subjects: 1620
Study 38610034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 g maltodextrin powder) diluted in 3 mL breastmilk per day until gestational week 34
Number of subjects: 1620
Study 38610034 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 1620
Study 38610034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study 38610138 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-facilitated telemedicine model for HCV treatment initiation
Number of subjects: 0
Study 38610925 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant systemic therapy (NAS) with immunotherapy (anti-PD-1, combination anti-CTLA-4 and anti-PD-1)
Number of subjects: 0
Study 38610925 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab as NAS therapy (3 doses)
Number of subjects: 0
Study 38610925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipilimumab + nivolumab as NAS therapy
Number of subjects: 0
Study 38610950 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) applied three times a week for 16 weeks
Number of subjects: 43
Study 38610950 — intervention group
Group type: EXPERIMENTAL
Intervention: sHLA-G levels in CIN before starting IMQ application
Number of subjects: 43
Study 38610966 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (STAMP inhibitor)
Number of subjects: 0
Study 38610966 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 38610966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib and Ponatinib (ATP site inhibitors)
Number of subjects: 0
Study 38611082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal Laser Ablation (TPLA) treatment, details on dosage and duration not available
Number of subjects: 0
Study 38611082 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38611586 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian women
Number of subjects: 408
Study 38611586 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged <35 years
Number of subjects: 408
Study 38611586 — intervention group
Group type: COMPARATOR
Intervention: Total study population
Number of subjects: 408
Study 38611595 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic analysis at diagnosis (D0)
Number of subjects: 34
Study 38611595 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic analysis at end of induction treatment (D33)
Number of subjects: 34
Study 38611595 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between common B-ALL and pre-B ALL
Number of subjects: 34
Study 38611595 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between D0 and D33
Number of subjects: 34
Study 38611595 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 38611689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Embolism Severity Index (PESI) calculated and reported in clinical record form on top of standard of care; experimental arm.
Number of subjects: 118
Study 38611689 — intervention group
Group type: COMPARATOR
Intervention: Standard of care; control arm.
Number of subjects: 118
Study 38613023 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalgae extract containing fucoxanthin for 12 weeks
Number of subjects: 37
Study 38613023 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalgae extract containing fucoxanthin
Number of subjects: 37
Study 38613023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study 38613092 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged fasting (3-12 days, <600 kcal/d)
Number of subjects: 176
Study 38613322 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition (IMN) with oral supplementation enriched with arginine, omega-3 fatty acids, and dietary nucleotides (Group 2)
Number of subjects: 50
Study 38613322 — intervention group
Group type: COMPARATOR
Intervention: Preoperative immunonutrition (IMN) followed by standard isocaloric nutrition (Group 1)
Number of subjects: 50
Study 38613329 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-EGFR (Group A: panitumumab)
Number of subjects: 588
Study 38613329 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-EGFR (Group B: cetuximab)
Number of subjects: 588
Study 38613329 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-VEGF (Group C: bevacizumab and aflibercept)
Number of subjects: 588
Study 38613372 — intervention group
Group type: EXPERIMENTAL
Intervention: CHORUS™ app access (intervention)
Number of subjects: 267
Study 38613372 — intervention group
Group type: COMPARATOR
Intervention: No app use (control)
Number of subjects: 267
Study 38613420 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses (ortho-k)
Number of subjects: 75
Study 38613420 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-vision spectacles (SVS)
Number of subjects: 75
Study 38613420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interviewing
Number of subjects: 75
Study 38613420 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch analysis
Number of subjects: 75
Study 38613420 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish version of PREP2
Number of subjects: 75
Study 38613425 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg once daily
Number of subjects: 64
Study 38613545 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate oral inhalation solution (FlecIH), single dose administered via oral inhalation over 8 minutes in a supervised medical setting.
Number of subjects: 98
Study 38613579 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced medial-lateral wall orbital decompression (BMLW-OD)
Number of subjects: 57
Study 38613579 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective 3-wall decompression (S3W-OD)
Number of subjects: 57
Study 38613579 — intervention group
Group type: COMPARATOR
Intervention: Both groups (BMLW-OD and S3W-OD)
Number of subjects: 57
Study 38613938 — intervention group
Group type: EXPERIMENTAL
Intervention: High PPI (> 1.5)
Number of subjects: 741
Study 38613938 — intervention group
Group type: COMPARATOR
Intervention: Low PPI (< 1.5) and Low Hb (< 9.7 g/dL)
Number of subjects: 741
Study 38614026 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning method for predicting neurocognitive outcomes
Number of subjects: 0
Study 38614026 — intervention group
Group type: COMPARATOR
Intervention: Current clinical practice
Number of subjects: 0
Study 38614026 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art method in label ranking
Number of subjects: 0
Study 38614240 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Diet Quality Score (PDQS) calculated from dietary data obtained from food frequency questionnaire, PrimeScreen, and 24-h recall.
Number of subjects: 1460
Study 38614240 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Diet Quality Score (PDQS)
Number of subjects: 1460
Study 38614279 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy in 8 fractions (stereotactic body radiation therapy)
Number of subjects: 30
Study 38614365 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Medical Services (EMS) transport
Number of subjects: 26305
Study 38614365 — intervention group
Group type: COMPARATOR
Intervention: Self-transport
Number of subjects: 26305
Study 38614372 — intervention group
Group type: EXPERIMENTAL
Intervention: 7T MRI assessment of hippocampal subfield volumes in AD patients
Number of subjects: 24
Study 38614372 — intervention group
Group type: EXPERIMENTAL
Intervention: UDSNB3.0 cognitive scores in AD patients
Number of subjects: 24
Study 38614372 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of Dentate Gyrus (DG) in AD patients
Number of subjects: 24
Study 38614372 — intervention group
Group type: EXPERIMENTAL
Intervention: CA1 volume in AD patients
Number of subjects: 24
Study 38614372 — intervention group
Group type: EXPERIMENTAL
Intervention: DG volume in AD patients
Number of subjects: 24
Study 38614372 — intervention group
Group type: EXPERIMENTAL
Intervention: CA1 and Tail volumes in AD patients
Number of subjects: 24
Study 38614372 — intervention group
Group type: EXPERIMENTAL
Intervention: 7T MRI as a diagnostic tool
Number of subjects: 24
Study 38614379 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Wobble Board Exercise Training (CWBET)
Number of subjects: 51